Alkem Laboratories Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/q7xk16f7y5ss4fmieplkqjqs.pdf

Key Takeaways


Domestic Business: Recovery and Portfolio Shift

Vikas Gupta: "So on a 3- to 5-year basis, clearly, I would see the pie changing. So today, we are at close to 17%, but I see upwards of 20% in the coming years as we move -- as we keep growing that business."

Margin Walk and Cost Structure

Vikas Gupta: "At 17%, I believe that should be sustainable. And going forward, we should look at improving it further. But that itself at 16% -- sorry, at 17% itself, we have 50 to 100 basis points improvement."

U.S. Business: Easing Erosion, Margin Recovery

Vikas Gupta: "So see U.S., the price erosion now is a single-digit price erosion, unlike the previous year's price erosion, which used to be a very high double-digit kind of price erosion. So I would say the prices are getting bottomed out."

International ex-U.S. and Biosimilars


Capital Allocation and Investment


Guidance & Commitments

CommitmentSpecificsTimeline
Full-year EBITDA marginClose the year at around 17%FY24 exit (Q4)
Sustainable margin floor17% EBITDA margin should be sustainable, with 50-100 bps improvement possible going forwardFY24 and beyond
Annual margin improvement100 bps improvement each year, guidance remainsOngoing, annual
R&D spend range4% to 4.5% of revenueComing years
Organic CapEx range₹300 crores to ₹350 croresOngoing
Biosimilar breakevenEnzene subsidiary to break evenThis year (FY24)
U.S. biosimilar facilityNew facility at ~₹250 crores, no further major CapEx thereafterNext 2 to 3 years
Tax rate10% to 12%At least next 2-3 years (through ~FY26)
Tax rate post-FY26Rise to 20% to 25% rangeAfter FY26
Chronic portfolio mixShift from ~17% to above 20% of portfolio3 to 5 years
Non-U.S. international growthGrowth momentum to continueFY25 and FY26
U.S. price erosionSingle-digit erosion expected to continueOngoing
API price levelsImprovement should stay at current levelsOngoing

Key Metrics

MetricQ3 FY24
Revenue growth~9% YoY
EBITDA margin21.3%, improved 160 bps YoY from 19.7%
Net profit after tax₹595 cr
Cash generated~₹600 cr during the quarter
YTD EBITDA margin18.9%
Full year EBITDA margin guidance~17%
Domestic business growth vs IPM+20 bps outperformance
Chronic contribution to domestic sales~17%
Antidiabetic portfolio growth~16%+, vs market growth of 5%
Other expenses₹740 cr, down from ₹811 cr in Q2; 22.3% of sales vs 23.6% in Q2
ANDA approvals6, including 1 tentative approval
Biosimilar business (Enzene) gross revenue~₹200 cr annual run rate
R&D spend3.4% of sales in Q3, expected to end year at ~4%
NLEM portfolio exposure28% to 32% of domestic sales
Effective tax rate11% to 12% for current and next year